← FDA DRUG APPROVALS

FDA NDA · NDA019898

PRAVACHOL

Sponsor: BRISTOL MYERS SQUIBB

APPLICATION
NDA019898
TYPE
NDA
ORIGINAL APPROVAL
1991-10-31
LATEST ACTION
2022-05-31
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

PRAVACHOL · ReferenceDiscontinued
PRAVASTATIN SODIUM 80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
PRAVACHOL · ReferenceDiscontinued
PRAVASTATIN SODIUM 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
PRAVACHOL · ReferenceDiscontinued
PRAVASTATIN SODIUM 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
PRAVACHOL · ReferenceDiscontinued
PRAVASTATIN SODIUM 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL

Approval history

2022-05-31Labeling · Supplement 70 · standardLetterAP
2020-09-25Labeling · Supplement 69 · 901 requiredLetterAP
2017-01-23Manufacturing (CMC) · Supplement 67 · standardAP
2016-07-05Labeling · Supplement 66 · standardLabelAP
2013-05-29Manufacturing (CMC) · Supplement 65 · standardAP
2012-10-31Labeling · Supplement 63 · 901 requiredLetterAP
2012-10-31Labeling · Supplement 64 · standardLetterAP
2012-02-28Labeling · Supplement 62 · unknownLabelAP
2011-05-18Labeling · Supplement 61 · standardLabelAP
2007-02-28Efficacy · Supplement 60 · unknownLabelAP
2005-07-06Labeling · Supplement 58 · standardLabelAP
2003-09-05Labeling · Supplement 54 · standardReviewAP
2002-10-29Efficacy · Supplement 52 · priorityLetterAP
2002-07-12Labeling · Supplement 50 · standardLabelAP
2002-06-14Manufacturing (CMC) · Supplement 51 · standardReviewAP
2002-01-14Manufacturing (CMC) · Supplement 49 · standardReviewAP
2001-12-18Efficacy · Supplement 46 · standardLetterAP
2001-08-13Manufacturing (CMC) · Supplement 45 · standardAP
2001-06-15Efficacy · Supplement 42 · standardLetterAP
2001-03-14Manufacturing (CMC) · Supplement 44 · standardReviewAP
2001-03-12Manufacturing (CMC) · Supplement 43 · standardReviewAP
2000-08-24Manufacturing (CMC) · Supplement 41 · standardReviewAP
2000-06-23Efficacy · Supplement 37 · standardReviewAP
2000-06-09Efficacy · Supplement 31 · standardReviewAP
2000-02-10Efficacy · Supplement 32 · unknownReviewAP
2000-01-18Efficacy · Supplement 30 · standardLetterAP
2000-01-18Efficacy · Supplement 29 · standardLetterAP
2000-01-18Efficacy · Supplement 27 · standardLetterAP
2000-01-18Efficacy · Supplement 26 · standardLetterAP
1999-10-14Manufacturing (CMC) · Supplement 35 · standardReviewAP
1999-10-14Efficacy · Supplement 34 · standardReviewAP
1999-09-13Labeling · Supplement 36 · standardReviewAP
1999-04-09Manufacturing (CMC) · Supplement 25 · standardReviewAP
1999-02-11Manufacturing (CMC) · Supplement 23 · standardReviewAP
1999-01-28Manufacturing (CMC) · Supplement 24 · standardReviewAP
1998-10-26Manufacturing (CMC) · Supplement 22 · standardAP
1998-08-17Labeling · Supplement 21 · standardAP
1998-05-20Labeling · Supplement 19 · standardAP
1998-03-27Efficacy · Supplement 18 · unknownReviewAP
1998-03-11Efficacy · Supplement 20 · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →